Pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy
The invention relates to a method of removing immune suppression in a tumor microenvironment or stimulating an immune system against cancer cells, comprising administering to a subject a combination of a HDAC inhibitor and an NSAID in combination with an immune checkpoint inhibitor.
1. A method of removing immune suppression in a colorectal cancer tumor microenvironment or stimulating an immune system against colorectal cancer cells, comprising administering to a subject an HDAC inhibitor, an NSAID and an immune checkpoint inhibitor, wherein
the HDAC inhibitor is selected from the group consisting of chidamide and entinostat;
the NSAID is celecoxib; and
the immune checkpoint inhibitor is anti-PD-1 antibody.
2. The method of claim 1 , wherein the method can inhibit or treat colorectal cancer through immunotherapy.
3. The method of claim 1 , wherein the combination further comprises a biguanide compound.
4. The method of claim 3 , wherein the biguanide compound is metformin, phenformin, proguanil or chlorproguanil.
5. The method of claim 1 , wherein the amounts of the HDAC inhibitor, the NSAID and the immune checkpoint inhibitor range from 10% (w/w) to 70% (w/w), 10% (w/w) to 70% (w/w) or 0.5% (w/w) to 20%, respectively.
6. The method of claim 3 , wherein the amount of biguanide compound ranges from 30% to 70% (w/w).
7. The method of claim 1 , which further comprises administering one or more additional anti-cancer agents.